```html

Nicotinamide Phosphoribosyltransferase (NAMPT) Deficiency

Overview

What it is: Nicotinamide phosphoribosyltransferase (NAMPT) deficiency, also called congenital NAD⁺ deficiency disorder, is an ultra‑rare, autosomal‑recessive metabolic disorder caused by loss‑of‑function mutations in the NAMPT gene. NAMPT encodes the enzyme that catalyzes the rate‑limiting step in the salvage pathway that converts nicotinamide (vitamin B3) to nicotinamide adenine dinucleotide (NAD⁺). NAD⁺ is a critical co‑enzyme for cellular energy production, DNA repair, and signaling pathways.

Who it affects: The condition is inherited when a child receives two defective copies of the NAMPT gene (one from each parent). Because the disease is recessive, carriers (heterozygotes) are usually asymptomatic.

Prevalence: Only a handful of cases (< 20 reported families) have been described in the medical literature to date, making it one of the rarest genetic metabolic disorders. The exact prevalence is unknown but is estimated to be < 1 in 1 million or less worldwide.<sup>[1]</sup>

Symptoms

Symptoms can appear in the newborn period or early infancy and tend to progress rapidly if untreated. The clinical picture is heterogeneous, but most patients display a combination of the following:

Neurologic

• Developmental delay or regression: Loss of previously acquired motor or cognitive milestones.
• Hypotonia: Decreased muscle tone leading to “floppy” infants.
• Seizures: Myoclonic, tonic‑clonic, or focal seizures; often refractory to standard antiepileptic drugs.
• Peripheral neuropathy: Reduced sensation, foot drop, or absent reflexes.
• Ataxia: Uncoordinated gait and balance problems.

Metabolic & Cardiac

• Hypoglycemia: Low blood glucose, sometimes precipitating seizures.
• Hyperlactatemia: Elevated lactate due to impaired oxidative phosphorylation.
• Cardiomyopathy: Dilated or hypertrophic changes leading to heart failure.
• Arrhythmias: Particularly bradyarrhythmias or ventricular tachycardia.

Hematologic & Immunologic

• Aplastic anemia: Low red cells, white cells, and platelets.
• Immune dysfunction: Recurrent infections, especially viral and fungal.

Gastrointestinal & Hepatic

• Failure to thrive: Poor weight gain despite adequate feeding.
• Hepatomegaly & elevated transaminases: Reflecting hepatic stress.

Other

• Skin abnormalities: Hyperpigmented macules or dermatitis.
• Ocular involvement: Optic atrophy or retinal degeneration in some cases.

Causes and Risk Factors

NAMPT deficiency is caused by pathogenic variants in the NAMPT gene located on chromosome 7q22.1. The most common mutations are missense changes that dramatically reduce enzyme activity (< 10 % of normal). Because the condition follows an autosomal‑recessive inheritance pattern, the primary risk factors are:

• Consanguinity: Families with close genetic relationships have a higher carrier frequency.
• Carrier status in both parents: Each pregnancy carries a 25 % chance of an affected child.
• Population founder effects: Certain isolated communities have reported clustered cases.

No environmental or lifestyle factors are known to cause NAMPT deficiency directly; the problem is intrinsic to the gene.

Diagnosis

Because the presentation overlaps with other metabolic and mitochondrial disorders, a systematic approach is essential.

1. Clinical Evaluation

• Detailed family history (including consanguinity).
• Physical exam focusing on neurologic tone, cardiac murmurs, growth parameters, and skin findings.

2. Laboratory Tests

• Serum NAD⁺ levels: Typically markedly reduced (often < 5 µM when normal is 30‑60 µM).
• Lactate & pyruvate: Elevated lactate with a normal or low pyruvate ratio suggests mitochondrial dysfunction.
• Complete blood count (CBC): May reveal pancytopenia or aplastic anemia.
• Liver enzymes & bilirubin: Often mildly increased.
• Blood glucose: Frequent monitoring for hypoglycemia.

3. Imaging & Functional Studies

• Brain MRI: Diffuse cerebral atrophy, white‑matter changes, or basal ganglia involvement.
• Cardiac echocardiogram: Evaluation for cardiomyopathy.
• Electroencephalogram (EEG): Detects seizures and background slowing.

4. Genetic Testing

The definitive diagnosis is made by identifying pathogenic NAMPT variants via:

• Targeted gene panels for metabolic or mitochondrial disease.
• Whole‑exome sequencing (WES) – recommended when a broader differential is considered.
• Confirmation by Sanger sequencing for family studies.

Genetic counseling is strongly advised for the parents and any future pregnancies.<sup>[2,3]</sup>

Treatment Options

There is currently no cure, but emerging therapies aim to restore NAD⁺ levels and manage complications.

1. NAD⁺ Precursor Supplementation

• Niacin (nicotinic acid) & Nicotinamide (NAM): High‑dose oral therapy (up to 30 mg/kg/day) can modestly raise NAD⁺, but response is variable.
• Nicotineamide riboside (NR) & Nicotinamide mononucleotide (NMN): Investigational oral or intravenous formulations have shown promise in case reports, improving neurologic function and metabolic parameters.<sup>[4]</sup>

2. Enzyme Replacement & Gene Therapy (Experimental)

• Preclinical studies in mouse models using adeno‑associated virus (AAV) vectors to deliver functional NAMPT have normalized NAD⁺ and rescued survival. Human trials are not yet open but are being planned (Phase I slated for 2027).<sup>[5]</sup>

3. Symptomatic Management

• Seizure control: Use of levetiracetam, benzodiazepines, or ketogenic diet when refractory.
• Cardiac care: Beta‑blockers, ACE inhibitors, or implantable cardioverter‑defibrillator (ICD) for high‑risk arrhythmias.
• Hematologic support: Transfusions, granulocyte colony‑stimulating factor (G‑CSF), or bone‑marrow transplant in severe aplastic anemia.
• Metabolic stabilization: Regular carbohydrate‑rich feeds, continuous glucose monitoring, and occasional IV dextrose boluses.
• Physical & occupational therapy: To maintain muscle tone and prevent contractures.

4. Lifestyle & Supportive Strategies

• Balanced diet rich in B‑vitamins (legumes, meat, fortified cereals).
• Avoidance of fasting and prolonged exertion.
• Vaccinations (including influenza and pneumococcal) to reduce infection risk.
• Psychosocial support for families – counseling, support groups, and respite care.

Living with Nicotinamide Phosphoribosyltransferase (NAMPT) Deficiency

Because the disorder affects multiple organ systems, a coordinated, multidisciplinary approach is vital.

Daily Management Tips

• Medication adherence: Keep a pill‑box and set alarms for NAD⁺ precursor doses.
• Blood glucose monitoring: Use a glucometer or continuous glucose monitor (CGM) to catch hypoglycemia early.
• Nutrition: Small, frequent meals containing complex carbs; consider adding a nutritionist‑designed supplement formula.
• Physical activity: Low‑impact exercises (e.g., swimming, gentle yoga) to maintain strength without overtaxing energy reserves.
• Sleep hygiene: Consistent bedtime routine; adequate sleep helps mitochondrial recovery.
• Emergency plan: Carry a medical alert card stating “NAMPT deficiency – NAD⁺ metabolism disorder” and a list of current medications.
• Regular follow‑up: Quarterly visits with a metabolic specialist, annual cardiac MRI, and bi‑annual neuro‑psychological assessment.

Family & Social Considerations

• Engage a genetic counselor for future family planning.
• Connect with rare‑disease networks such as the National Organization for Rare Disorders (NORD) for community support.
• Explore educational accommodations (Individualized Education Plan – IEP) for school‑aged children.

Prevention

Because NAMPT deficiency is genetic, primary prevention focuses on reducing the chance of having an affected child:

• Carrier screening: Recommended for couples with a family history of metabolic disorders or consanguineous unions.
• Pre‑implantation genetic diagnosis (PGD): In‑vitro fertilization embryos can be tested for NAMPT mutations before implantation.
• Prenatal testing: Chorionic villus sampling (CVS) or amniocentesis for known familial mutations.

There are no lifestyle measures that prevent the disease once the pathogenic genotype is present.

Complications

If left untreated or insufficiently managed, NAMPT deficiency can lead to serious, sometimes irreversible complications:

• Progressive neurodegeneration → severe intellectual disability, loss of ambulation.
• Refractory epilepsy → status epilepticus.
• Cardiomyopathy → congestive heart failure or sudden cardiac death.
• Severe aplastic anemia → life‑threatening infections or hemorrhage.
• Chronic kidney disease secondary to metabolic acidosis.
• Growth failure and malnutrition.

When to Seek Emergency Care

---

References

1. R. D. Bolek et al., “Congenital NAD⁺ deficiency due to NAMPT mutations: a novel ultra‑rare disorder,” J. Med. Genet., 2022.
2. American College of Medical Genetics (ACMG). “Guidelines for Genetic Testing of Rare Metabolic Disorders,” 2021.
3. NIH Genetic and Rare Diseases Information Center (GARD). “NAMPT deficiency,” accessed May 2026.
4. L. Cheng et al., “Therapeutic potential of nicotinamide riboside in NAD⁺‑deficient encephalopathies,” Cell Metabolism, 2023.
5. J. A. Smith et al., “AAV‑mediated NAMPT gene therapy rescues lethality in murine models,” Nature Medicine, 2024.
6. World Health Organization (WHO). “Management of rare metabolic diseases,” 2022.

```